QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab
The product can be used by any lab that conducts NGS testing, making precision medicine accessible to all cancer patients
Both companies aim to improve the efficiency and success rate of the current drug discovery process.
Advances deployment of mRNA technology across vaccines and therapeutics development
Innovative solutions and a deep understanding of the market makes this a unique combination
Startup receives US $ 5 million in first round of funding
Ultreon 1.0 Software, the first-of-its-kind imaging software, merges optical coherence tomography with the power of automation using AI -
The company posted net profit of Rs.9.06 crores for the period ended June 30, 2020.
The contribution of Wockhardt at Wrexham is one of the best examples of the success and significant potential of India-UK partnerships in the healthcare sector
Winlevi has been approved by the United States FDA as a novel drug with a unique mechanism of action for the topical treatment of acne in patients 12 years and older
Subscribe To Our Newsletter & Stay Updated
